Kuros BiosciencesCSBTF 71 OCF Margin % is 1.76% as of Dec. 2025. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $54.72 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 61.96% on this metric.
The historical rank and industry rank for Kuros Biosciences's OCF Margin % or its related term are showing as below:
CSBTF'
s OCF Margin % Range Over the Past 10 Years
Min: -1999.63 Med: -134.8 Max: 4.16
Current: -0.28
During the past 13 years, the highest OCF Margin % of Kuros Biosciences was 4.16%. The lowest was -1999.63%. And the median was -134.80%.
CSBTF's OCF Margin % is ranked worse than 61.96% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 5.86
vs CSBTF: -0.28
Kuros Biosciences OCF Margin % Related Terms
Kuros Biosciences OCF Margin % Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Kuros Biosciences's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (CSBTF) has a OCF Margin % of 1.76% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kuros Biosciences and its competitors. According to the industry distribution chart, Kuros Biosciences ranks #505 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 62%.
Is Kuros Biosciences' OCF Margin % too high?
Kuros Biosciences' current OCF Margin % is 1.76%. The Medical Devices & Instruments industry median OCF Margin % is 5.86. Kuros Biosciences' value of 1.76% is 70% below this industry median. Based on the distribution chart, Kuros Biosciences ranks #505 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' OCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #505 out of 815 companies for OCF Margin %. This places Kuros Biosciences in the lower half of its industry. The industry median OCF Margin % is 5.86. Kuros Biosciences' value of 1.76% is 70% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.86, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current OCF Margin % of 1.76% is 70% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current OCF Margin % is 1.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.72, compared to a current price of $22.72 — trading 58.5% below its estimated fair value. The current OCF Margin % is 1.76% and 70% below the Medical Devices & Instruments industry median of 5.86. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current OCF Margin % is 1.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $22.72 is trading 58.5% below its estimated GF Value™ of $54.72.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
OCF Margin %: 1.76%
GF Value™: $54.72 vs. price of $22.72 (58.5% below fair value)
Industry Position: 70% below the Medical Devices & Instruments median (#505 of 815)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score
Get the complete analysis for CSBTF
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
